tqb2858
Recombinant proteinexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 23, 2021 (NCT04805060)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1ANTAGONIST
CD274 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05262101 | Phase 2 | Mar 31, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05193604 | Phase 1 | Mar 24, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05198531 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2022 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05154630 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05121363 | Phase 2 | Dec 31, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05068921 | Phase 1 | Oct 31, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT04805060 | Phase 1 | Apr 23, 2021 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 7 | 7 | 2 | 2021 |
1 organizations
Page 1 / 1